| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0264-410X(03)00032-X |
| P698 | PubMed publication ID | 12744881 |
| P50 | author | Mariano Esteban | Q30004051 |
| P2093 | author name string | Vicente Larraga | |
| Javier Lucientes | |||
| Tobias Hanke | |||
| Dolores Rodriguez | |||
| Juan A Castillo | |||
| Juan J Zárate | |||
| Juan R Rodriguez | |||
| Maria J Ramiro | |||
| P2860 | cites work | DNA vaccines: immunology, application, and optimization* | Q28145651 |
| Measurement of antigen specific lymphocyte proliferation using 5-bromo-deoxyuridine incorporation. An easy and low cost alternative to radioactive thymidine incorporation | Q28333351 | ||
| Induction and abrogation of LACK reactive cells in the evolution of human leishmaniasis | Q28367592 | ||
| Molecular cloning, cell localization and binding affinity to DNA replication proteins of the p36/LACK protective antigen from Leishmania infantum | Q30657332 | ||
| The prime-boost strategy: exciting prospects for improved vaccination | Q33876983 | ||
| Control of Leishmania infantum infection is associated with CD8(+) and gamma interferon- and interleukin-5-producing CD4(+) antigen-specific T cells | Q34002287 | ||
| Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis | Q34008441 | ||
| A striking property of recombinant poxviruses: efficient inducers of in vivo expansion of primed CD8(+) T cells | Q34132562 | ||
| Th1- and Th2-cell commitment during infectious disease: asymmetry in divergent pathways | Q34319955 | ||
| An update on antileishmanial vaccine candidates and prospects for a canine Leishmania vaccine | Q34346535 | ||
| Cellular and humoral immune responses in dogs experimentally and naturally infected with Leishmania infantum | Q35771655 | ||
| Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major | Q36380692 | ||
| Expression cloning of a protective Leishmania antigen | Q36701227 | ||
| Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques | Q36952733 | ||
| Taxonomy of Leishmania. Use of isoenzymes. Suggestions for a new classification | Q37784381 | ||
| Latent class analysis permits unbiased estimates of the validity of DAT for the diagnosis of visceral leishmaniasis | Q38912962 | ||
| Multi-centre evaluation of repeatability and reproducibility of the direct agglutination test for visceral leishmaniasis | Q38912965 | ||
| Class II major histocompatibility complex-deficient mice initially control an infection with Leishmania major but succumb to the disease | Q38937098 | ||
| T-cell responses to immunodominant LACK antigen do not play a critical role in determining susceptibility of BALB/c mice to Leishmania mexicana | Q39518100 | ||
| Suppression of both antimony-susceptible and antimony-resistant Leishmania donovani by a bis(benzyl)polyamine analog | Q39815819 | ||
| The regulation of immunity to Leishmania major | Q40444839 | ||
| Lymphocyte responses and cytokines | Q40620203 | ||
| Immunology taught by viruses | Q40933905 | ||
| A human immunodeficiency virus type 1 Env-granulocyte-macrophage colony-stimulating factor fusion protein enhances the cellular immune response to Env in a vaccinia virus-based vaccine | Q40975026 | ||
| The contrasting roles of CD4+ T cells in intracellular infections in humans: leishmaniasis as an example | Q40999681 | ||
| The expanding universe of T-cell subsets: Th1, Th2 and more. | Q41120396 | ||
| Early suppression of lymphoproliferative response in dogs with natural infection by Leishmania infantum | Q43214563 | ||
| Protective immune response against cutaneous leishmaniasis by prime/booster immunization regimens with vaccinia virus recombinants expressing Leishmania infantum p36/LACK and IL-12 in combination with purified p36. | Q43698528 | ||
| Helper T cells without CD4: control of leishmaniasis in CD4-deficient mice | Q43806211 | ||
| A heterologous prime-boost regime using DNA and recombinant vaccinia virus expressing the Leishmania infantum P36/LACK antigen protects BALB/c mice from cutaneous leishmaniasis. | Q43861566 | ||
| A reverse transcription-polymerase chain reaction technique to detect feline cytokine genes | Q44862699 | ||
| Genetic vaccination against leishmaniasis | Q45026373 | ||
| IL-4-secreting CD4+ T cells are crucial to the development of CD8+ T-cell responses against malaria liver stages. | Q47898789 | ||
| Infective inoculum for Leishmania. | Q52596058 | ||
| Vaccination trial against canine visceral leishmaniasis. Phocean Veterinary Study Group on Visceral Leishmaniasis. | Q54349473 | ||
| ALeishmaniaHomologue of Receptors for Activated C‐Kinase (LACK) Induces Both Interferon‐γ and Interleukin‐10 in Natural Killer Cells of Healthy Blood Donors | Q58779522 | ||
| Type 2 Cytokine Gene Activation and Its Relationship to Extent of Disease in Patients with Tuberculosis | Q58826841 | ||
| Serological and parasitological follow-up in dogs experimentally infected with Leishmania infantum and treated with meglumine antimoniate | Q58852077 | ||
| Immunological and histological study of T- and B-lymphocyte activity in canine visceral leishmaniosis | Q72293903 | ||
| Epidermal immunocompetence in canine leishmaniasis | Q73510664 | ||
| Tissue cytokine responses in canine visceral leishmaniasis | Q73732906 | ||
| The Ibizian hound presents a predominantly cellular immune response against natural Leishmania infection | Q73828239 | ||
| Effect of intragastric and intraperitoneal immunisation with attenuated and wild-type LACK-expressing Listeria monocytogenes on control of murine Leishmania major infection | Q74188180 | ||
| IL-4 instructs TH1 responses and resistance to Leishmania major in susceptible BALB/c mice | Q74619595 | ||
| Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection | Q77658710 | ||
| P433 | issue | 19-20 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Leishmania infantum | Q1950789 |
| visceral leishmaniasis | Q2046113 | ||
| P1104 | number of pages | 11 | |
| P304 | page(s) | 2474-2484 | |
| P577 | publication date | 2003-06-01 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACK | |
| P478 | volume | 21 |
| Q52687615 | A killed Leishmania vaccine with sand fly saliva extract and saponin adjuvant displays immunogenicity in dogs. |
| Q52662748 | A large-scale field randomized trial demonstrates safety and efficacy of the vaccine LetiFend® against canine leishmaniosis. |
| Q37144722 | A prime/boost DNA/Modified vaccinia virus Ankara vaccine expressing recombinant Leishmania DNA encoding TRYP is safe and immunogenic in outbred dogs, the reservoir of zoonotic visceral leishmaniasis |
| Q21131835 | An Insight into the proteome of Crithidia fasciculata choanomastigotes as a comparative approach to axenic growth, peanut lectin agglutination and differentiation of Leishmania spp. promastigotes |
| Q61690576 | Antibiotic resistance free plasmid DNA expressing LACK protein leads towards a protective Th1 response against Leishmania infantum infection |
| Q64935233 | Assessment of Vaccine-Induced Immunity Against Canine Visceral Leishmaniasis. |
| Q41522732 | Canine Leishmania vaccines: still a long way to go. |
| Q35927516 | Canine leishmaniasis |
| Q38100045 | Case study for a vaccine against leishmaniasis |
| Q28539852 | Clinical and parasitological protection in a Leishmania infantum-macaque model vaccinated with adenovirus and the recombinant A2 antigen |
| Q41768625 | Cloning and Expression of Recombinant Plasmid Containing P36/LACK Gene of Leishmania infantum Iranian Strain. |
| Q35587034 | Coadministration of the Three Antigenic Leishmania infantum Poly (A) Binding Proteins as a DNA Vaccine Induces Protection against Leishmania major Infection in BALB/c Mice |
| Q38927526 | Current status on prevention and treatment of canine leishmaniasis |
| Q36915067 | DNA Vaccines against Protozoan Parasites: Advances and Challenges |
| Q33208276 | DNA vaccines and their application against parasites--promise, limitations and potential solutions. |
| Q24801950 | DNA vaccines: designing strategies against parasitic infections |
| Q40422839 | Detailed analysis of an experimental challenge model for Leishmania infantum (JPC strain) in dogs |
| Q35207606 | Development of Vaccines against Visceral Leishmaniasis |
| Q36171324 | Diagnostic value of conjunctival swab sampling associated with nested PCR for different categories of dogs naturally exposed to Leishmania infantum infection |
| Q58098436 | Ecoepidemiological aspects of visceral leishmaniasis in an endemic area in the Steel Valley in Brazil: An ecological approach with spatial analysis |
| Q47587014 | Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine. |
| Q33843258 | Enhanced breadth of CD4 T-cell immunity by DNA prime and adenovirus boost immunization to human immunodeficiency virus Env and Gag immunogens |
| Q52659559 | Failure of a multi-subunit recombinant leishmanial vaccine (MML) to protect dogs from Leishmania infantum infection and to prevent disease progression in infected animals. |
| Q41404819 | Head-to-head comparison of three vaccination strategies based on DNA and raw insect-derived recombinant proteins against Leishmania. |
| Q61690623 | Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response |
| Q42957095 | Heterologous prime-boost vaccination with the LACK antigen protects against murine visceral leishmaniasis |
| Q64115313 | IL12 p35 and p40 subunit genes administered as pPAL plasmid constructs do not improve protection of pPAL-LACK vaccine against canine leishmaniasis |
| Q33693899 | Identifying vaccine targets for anti-leishmanial vaccine development |
| Q81049997 | Immunization strategies against visceral leishmaniosis with the nucleosomal histones of Leishmania infantum encoded in DNA vaccine or pulsed in dendritic cells |
| Q37225443 | Immunization with H1, HASPB1 and MML Leishmania proteins in a vaccine trial against experimental canine leishmaniasis. |
| Q46832650 | Immunization with the cysteine proteinase Ldccys1 gene from Leishmania (Leishmania) chagasi and the recombinant Ldccys1 protein elicits protective immune responses in a murine model of visceral leishmaniasis |
| Q45197095 | Immunogenicity assay of the Leishmune vaccine against canine visceral leishmaniasis in Brazil |
| Q58898218 | Immunogenicity of HSP-70, KMP-11 and PFR-2 leishmanial antigens in the experimental model of canine visceral leishmaniasis |
| Q53609100 | Immunogenicity of a multicomponent DNA vaccine against visceral leishmaniasis in dogs. |
| Q36945381 | Immunogenicity of the P-8 amastigote antigen in the experimental model of canine visceral leishmaniasis |
| Q36536651 | Immunology of canine leishmaniasis |
| Q34650461 | Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune vaccine |
| Q43267738 | Immunotherapy with the saponin enriched-Leishmune vaccine versus immunochemotherapy in dogs with natural canine visceral leishmaniasis. |
| Q39005594 | Induction of immunogenicity by live attenuated Leishmania donovani centrin deleted parasites in dogs |
| Q58824983 | Intramuscular immunization with p36(LACK) DNA vaccine induces IFN-γ production but does not protect BALB/c mice against Leishmania chagasi intravenous challenge |
| Q79616020 | Intranasal delivery of naked DNA encoding the LACK antigen leads to protective immunity against visceral leishmaniasis in mice |
| Q36446275 | Intranasal vaccination against cutaneous leishmaniasis with a particulated leishmanial antigen or DNA encoding LACK. |
| Q36726750 | Leishmania vaccines: progress and problems. |
| Q47556262 | Leishmaniasis in humans: drug or vaccine therapy? |
| Q36496298 | Leishmune vaccine: the newest tool for prevention and control of canine visceral leishmaniosis and its potential as a transmission-blocking vaccine |
| Q58853389 | Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: Double-blind randomised efficacy field trial |
| Q52704499 | Longitudinal study on the detection of canine Leishmania infections by conjunctival swab analysis and correlation with entomological parameters. |
| Q46553640 | Lymphocytes of dogs immunised with purified excreted-secreted antigens of Leishmania infantum co-incubated with Leishmania infected macrophages produce IFN gamma resulting in nitric oxide-mediated amastigote apoptosis. |
| Q60227744 | Nucleoside hydrolase DNA vaccine against canine visceral leishmaniasis |
| Q45410872 | Prime-boost immunization with DNA followed by a recombinant vaccinia virus expressing P50 induced protective immunity against Babesia gibsoni infection in dogs |
| Q46394444 | Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes |
| Q34604577 | Safety trial using the Leishmune vaccine against canine visceral leishmaniasis in Brazil. |
| Q47962483 | Selection of appropriate serological tests to measure the incidence of natural Leishmania infantum infection during DNA/MVA prime/boost canine vaccine trials |
| Q39830555 | Seroreactivity against raw insect-derived recombinant KMPII, TRYP, and LACK Leishmania infantum proteins in infected dogs. |
| Q43486818 | T-cell-derived cytokines, nitric oxide production by peripheral blood monocytes and seric anti-Leishmania (Leishmania) chagasi IgG subclass patterns following immunization against canine visceral leishmaniasis using Leishvaccine and Leishmune |
| Q90639766 | The Delay in the Licensing of Protozoal Vaccines: A Comparative History |
| Q26830601 | The prevention of canine leishmaniasis and its impact on public health |
| Q46953999 | Towards a metalloprotease-DNA vaccine against piscine cryptobiosis caused by Cryptobia salmositica |
| Q35972642 | Towards development of novel immunization strategies against leishmaniasis using PLGA nanoparticles loaded with kinetoplastid membrane protein-11 |
| Q43223330 | Vaccination with plasmid DNA encoding KMPII, TRYP, LACK and GP63 does not protect dogs against Leishmania infantum experimental challenge |
| Q56769198 | Vaccines for canine leishmaniasis |
| Q34754538 | Vaccines for leishmaniasis in the fore coming 25 years. |
| Q34511559 | Vaccines to prevent leishmaniasis |
| Q34076804 | Visceral Leishmaniasis: Advancements in Vaccine Development via Classical and Molecular Approaches |
| Q40712313 | Zoonotic visceral leishmaniasis transmission: modeling, backward bifurcation, and optimal control |
Search more.